Approaches to interchain cysteine-linked adc characterization by mass spectrometry

Molecular Pharmaceutics

Volumn 12, Issue 6, 2015, Pages 1774-1783

  Valliere Douglass, John F ^a   Hengel, Shawna M ^a   Pan, Lucy Y ^a  

^a SEATTLE GENETICS INC   (United States)

Author keywords

ADC; antibody drug conjugate; auristatin; drug distribution; HDX MS; higher order structure; hydrogen deuterium exchange; mass spectrometry; pharmacokinetics

Indexed keywords

CYSTEINE; CYTOTOXIC AGENT; MONOCLONAL ANTIBODY; ANTIBODY CONJUGATE;

ARTICLE; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; DEUTERIUM HYDROGEN EXCHANGE; DRUG CONJUGATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL PERMEATION CHROMATOGRAPHY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; X RAY CRYSTALLOGRAPHY; ANIMAL; CHEMISTRY; HUMAN; PROCEDURES;

ANIMALS; CYSTEINE; HUMANS; IMMUNOCONJUGATES; MASS SPECTROMETRY;

EID: 84930657941     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500614p     Document Type: Article

References (82)

1. Alley, S. C.; Zhang, X.; Okeley, N. M.; Anderson, M.; Law, C. L.; Senter, P. D.; Benjamin, D. R. The pharmacologic basis for antibody-auristatin conjugate activity J. Pharmacol. Exp. Ther. 2009, 330, 932-8
2. Ikeda, H.; Hideshima, T.; Fulciniti, M.; Lutz, R. J.; Yasui, H.; Okawa, Y.; Kiziltepe, T.; Vallet, S.; Pozzi, S.; Santo, L. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo Clin. Cancer Res. 2009, 15, 4028-37
3. Lutz, R. J.; Whiteman, K. R. Antibody-maytansinoid conjugates for the treatment of myeloma MAbs 2009, 1, 548-51
4. Doronina, S. O.; Toki, B. E.; Torgov, M. Y.; Mendelsohn, B. A.; Cerveny, C. G.; Chace, D. F.; DeBlanc, R. L. Gearing RP, Bovee TD, Siegall CB, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy Nat. Biotechnol. 2003, 21, 778-84
5. Senter, P. D.; Sievers, E. L. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma Nat. Biotechnol. 2012, 30, 631-7
6. Sun, M. M.; Beam, K. S.; Cerveny, C. G.; Hamblett, K. J.; Blackmore, R. S.; Torgov, M. Y.; Handley, F. G.; Ihle, N. C.; Senter, P. D.; Alley, S. C. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides Bioconjugate Chem. 2005, 16, 1282-90
7. Lewis Phillips, G. D.; Li, G.; Dugger, D. L.; Crocker, L. M.; Parsons, K. L.; Mai, E.; Blattler, W. A.; Lambert, J. M.; Chari, R. V.; Lutz, R. J. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res. 2008, 68, 9280-90
8. Blanc, V.; Bousseau, A.; Caron, A.; Carrez, C.; Lutz, R. J.; Lambert, J. M. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies Clin. Cancer Res. 2011, 17, 6448-58
9. Wang, L.; Amphlett, G.; Blattler, W. A.; Lambert, J. M.; Zhang, W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry Protein Sci. 2005, 14, 2436-46
10. McDonagh, C. F.; Turcott, E.; Westendorf, L.; Webster, J. B.; Alley, S. C.; Kim, K.; Andreyka, J.; Stone, I.; Hamblett, K. J.; Francisco, J. A. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment Protein Eng., Des. Sel. 2006, 19, 299-307
11. Hartley, J. A.; Hamaguchi, A.; Coffils, M.; Martin, C. R.; Suggitt, M.; Chen, Z.; Gregson, S. J.; Masterson, L. A.; Tiberghien, A. C.; Hartley, J. M. SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity Cancer Res. 2010, 70, 6849-58
12. Hartley, J. A.; Spanswick, V. J.; Brooks, N.; Clingen, P. H.; McHugh, P. J.; Hochhauser, D.; Pedley, R. B.; Kelland, L. R.; Alley, M. C.; Schultz, R. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity Cancer Res. 2004, 64, 6693-9
13. Jeffrey, S. C.; Burke, P. J.; Lyon, R. P.; Meyer, D. W.; Sussman, D.; Anderson, M.; Hunter, J. H.; Leiske, C. I.; Miyamoto, J. B.; Nicholas, N. D. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology Bioconjugate Chem. 2013, 24, 1256-63
14. Kung Sutherland, M. S.; Walter, R. B.; Jeffrey, S. C.; Burke, P. J.; Yu, C.; Kostner, H.; Stone, I.; Ryan, M. C.; Sussman, D.; Lyon, R. P. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML Blood 2013, 122, 1455-63
15. Dornan, D.; Bennett, F.; Chen, Y.; Dennis, M.; Eaton, D.; Elkins, K.; French, D.; Go, M. A.; Jack, A.; Junutula, J. R. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma Blood 2009, 114, 2721-9
16. Junutula, J. R.; Raab, H.; Clark, S.; Bhakta, S.; Leipold, D. D.; Weir, S.; Chen, Y.; Simpson, M.; Tsai, S. P.; Dennis, M. S. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 2008, 26, 925-32
17. Strop, P. Versatility of Microbial Transglutaminase Bioconjugate Chem. 2014, 25 (5) 855-62
18. Axup, J. Y.; Bajjuri, K. M.; Ritland, M.; Hutchins, B. M.; Kim, C. H.; Kazane, S. A.; Halder, R.; Forsyth, J. S.; Santidrian, A. F.; Stafin, K. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 16101-6
19. Smith, E. L.; Giddens, J. P.; Iavarone, A. T.; Godula, K.; Wang, L. X.; Bertozzi, C. R. Chemoenzymatic Fc glycosylation via engineered aldehyde tags Bioconjugate Chem. 2014, 25, 788-95
20. Wakankar, A.; Chen, Y.; Gokarn, Y.; Jacobson, F. S. Analytical methods for physicochemical characterization of antibody drug conjugates MAbs 2011, 3, 161-72
21. Chari, R. V.; Martell, B. A.; Gross, J. L.; Cook, S. B.; Shah, S. A.; Blattler, W. A.; McKenzie, S. J.; Goldmacher, V. S. Immunoconjugates containing novel maytansinoids: promising anticancer drugs Cancer Res. 1992, 52, 127-31
22. Hamblett, K. J.; Senter, P. D.; Chace, D. F.; Sun, M. M.; Lenox, J.; Cerveny, C. G.; Kissler, K. M.; Bernhardt, S. X.; Kopcha, A. K.; Zabinski, R. F. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin. Cancer Res. 2004, 10, 7063-70
23. Laguzza, B. C.; Nichols, C. L.; Briggs, S. L.; Cullinan, G. J.; Johnson, D. A.; Starling, J. J.; Baker, A. L.; Bumol, T. F.; Corvalan, J. R. New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity J. Med. Chem. 1989, 32, 548-55
24. Le, L. N.; Moore, J. M.; Ouyang, J.; Chen, X.; Nguyen, M. D.; Galush, W. J. Profiling antibody drug conjugate positional isomers: a system-of-equations approach Anal. Chem. 2012, 84, 7479-86
25. Siegel, M. M.; Hollander, I. J.; Hamann, P. R.; James, J. P.; Hinman, L.; Smith, B. J.; Farnsworth, A. P.; Phipps, A.; King, D. J.; Karas, M. Matrix-assisted UV-laser desorption/ionization mass spectrometric analysis of monoclonal antibodies for the determination of carbohydrate, conjugated chelator, and conjugated drug content Anal. Chem. 1991, 63, 2470-81
26. Siegel, M. M.; Tabei, K.; Kunz, A.; Hollander, I. J.; Hamann, R. R.; Bell, D. H.; Berkenkamp, S.; Hillenkamp, F. Calicheamicin derivatives conjugated to monoclonal antibodies: determination of loading values and distributions by infrared and UV matrix-assisted laser desorption/ionization mass spectrometry and electrospray ionization mass spectrometry Anal. Chem. 1997, 69, 2716-26
27. Rosati, S.; Thompson, N. J.; Barendregt, A.; Hendriks, L. J.; Bakker, A. B.; de Kruif, J.; Throsby, M.; van Duijn, E.; Heck, A. J. Qualitative and semiquantitative analysis of composite mixtures of antibodies by native mass spectrometry Anal. Chem. 2012, 84, 7227-32
28. Rosati, S.; van den Bremer, E. T.; Schuurman, J.; Parren, P. W.; Kamerling, J. P.; Heck, A. J. In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap MAbs 2013, 5 (6) 917-24
29. Rosati, S.; Yang, Y.; Barendregt, A.; Heck, A. J. Detailed mass analysis of structural heterogeneity in monoclonal antibodies using native mass spectrometry Nat. Protoc. 2014, 9, 967-76
30. Lazar, A. C.; Wang, L.; Blattler, W. A.; Amphlett, G.; Lambert, J. M.; Zhang, W. Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry Rapid Commun. Mass Spectrom. 2005, 19, 1806-14
31. Chen, X. N.; Nguyen, M.; Jacobson, F.; Ouyang, J. Charge-based analysis of antibodies with engineered cysteines: from multiple peaks to a single main peak MAbs 2009, 1, 563-71
32. Reid, C. Q.; Tait, A.; Baldascini, H.; Mohindra, A.; Racher, A.; Bilsborough, S.; Smales, C. M.; Hoare, M. Rapid whole monoclonal antibody analysis by mass spectrometry: An ultra scale-down study of the effect of harvesting by centrifugation on the post-translational modification profile Biotechnol. Bioeng. 2010, 107, 85-95
33. Shen, B. Q.; Xu, K.; Liu, L.; Raab, H.; Bhakta, S.; Kenrick, M.; Parsons-Reponte, K. L.; Tien, J.; Yu, S. F.; Mai, E. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates Nat. Biotechnol. 2012, 30, 184-9
34. Bondarenko, P. V.; Second, T. P.; Zabrouskov, V.; Makarov, A. A.; Zhang, Z. Mass measurement and top-down HPLC/MS analysis of intact monoclonal antibodies on a hybrid linear quadrupole ion trap-Orbitrap mass spectrometer J. Am. Soc. Mass Spectrom. 2009, 20, 1415-24
35. Lossl, P.; Snijder, J.; Heck, A. J. Boundaries of mass resolution in native mass spectrometry J. Am. Soc. Mass Spectrom. 2014, 25, 906-17
36. Chen, J.; Yin, S.; Wu, Y.; Ouyang, J. Development of a native nanoelectrospray mass spectrometry method for determination of the drug-to-antibody ratio of antibody-drug conjugates Anal. Chem. 2013, 85, 1699-704
37. Valliere-Douglass, J. F.; McFee, W. A.; Salas-Solano, O. Native intact mass determination of antibodies conjugated with monomethyl Auristatin E and F at interchain cysteine residues Anal. Chem. 2012, 84, 2843-9
38. Debaene, F.; Boeuf, A.; Wagner-Rousset, E.; Colas, O.; Ayoub, D.; Corvaia, N.; Van Dorsselaer, A.; Beck, A.; Cianferani, S. Innovative Native MS Methodologies for Antibody Drug Conjugate Characterization: High Resolution Native MS and IM-MS for Average DAR and DAR Distribution Assessment Anal. Chem. 2014, 86, 10674-83
39. Rosati, S.; Rose, R. J.; Thompson, N. J.; van Duijn, E.; Damoc, E.; Denisov, E.; Makarov, A.; Heck, A. J. Exploring an orbitrap analyzer for the characterization of intact antibodies by native mass spectrometry Angew. Chem., Int. Ed. 2012, 51, 12992-6
40. Hengel, S. M.; Sanderson, R.; Valliere-Douglass, J.; Nicholas, N.; Leiske, C.; Alley, S. C. Measurement of in vivo drug load distribution of cysteine-linked antibody-drug conjugates using microscale liquid chromatography mass spectrometry Anal. Chem. 2014, 86, 3420-5
41. Xu, K.; Liu, L.; Saad, O. M.; Baudys, J.; Williams, L.; Leipold, D.; Shen, B.; Raab, H.; Junutula, J. R.; Kim, A. Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry Anal. Biochem. 2011, 412, 56-66
42. Joubert, M. K.; Hokom, M.; Eakin, C.; Zhou, L.; Deshpande, M.; Baker, M. P.; Goletz, T. J.; Kerwin, B. A.; Chirmule, N.; Narhi, L. O. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses J. Biol. Chem. 2012, 287, 25266-79
43. Rosenberg, A. S. Effects of protein aggregates: an immunologic perspective AAPS J. 2006, 8, E501-7
44. Englander, S. W.; Mayne, L. Protein folding studied using hydrogen-exchange labeling and two-dimensional NMR Annu. Rev. Biophys. Biomol. Struct. 1992, 21, 243-65
45. Foster, M. P.; McElroy, C. A.; Amero, C. D. Solution NMR of large molecules and assemblies Biochemistry 2007, 46, 331-40
46. Saphire, E. O.; Parren, P. W.; Pantophlet, R.; Zwick, M. B.; Morris, G. M.; Rudd, P. M.; Dwek, R. A.; Stanfield, R. L.; Burton, D. R.; Wilson, I. A. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design Science 2001, 293, 1155-9
47. Houde, D.; Arndt, J.; Domeier, W.; Berkowitz, S.; Engen, J. R. Characterization of IgG1 Conformation and Conformational Dynamics by Hydrogen/Deuterium Exchange Mass Spectrometry Anal. Chem. 2009, 81, 5966
48. Houde, D.; Berkowitz, S. A.; Engen, J. R. The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies J. Pharm. Sci. 2011, 100, 2071-86
49. Houde, D.; Engen, J. R. Conformational analysis of recombinant monoclonal antibodies with hydrogen/deuterium exchange mass spectrometry Methods Mol. Biol. 2013, 988, 269-89
50. Dharmasiri, K.; Smith, D. L. Mass spectrometric determination of isotopic exchange rates of amide hydrogens located on the surfaces of proteins Anal. Chem. 1996, 68, 2340-4
51. Englander, S. W.; Sosnick, T. R.; Englander, J. J.; Mayne, L. Mechanisms and uses of hydrogen exchange Curr. Opin. Struct. Biol. 1996, 6, 18-23
52. Smith, D. L.; Deng, Y.; Zhang, Z. Probing the non-covalent structure of proteins by amide hydrogen exchange and mass spectrometry J. Mass Spectrom. 1997, 32, 135-46
53. Burkitt, W.; Domann, P.; O'Connor, G. Conformational changes in oxidatively stressed monoclonal antibodies studied by hydrogen exchange mass spectrometry Protein Sci. 2010, 19, 826-35
54. Hawe, A.; Kasper, J. C.; Friess, W.; Jiskoot, W. Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress Eur. J. Pharm. Sci. 2009, 38, 79-87
55. Zhang, A.; Singh, S. K.; Shirts, M. R.; Kumar, S.; Fernandez, E. J. Distinct aggregation mechanisms of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange Pharm. Res. 2012, 29, 236-50
56. Houde, D.; Peng, Y.; Berkowitz, S. A.; Engen, J. R. Post-translational modifications differentially affect IgG1 conformation and receptor binding Mol. Cell Proteomics 2010, 9, 1716-28
57. Pan, L. Y.; Salas-Solano, O.; Valliere-Douglass, J. F. Conformation and dynamics of interchain cysteine-linked antibody-drug conjugates as revealed by hydrogen/deuterium exchange mass spectrometry Anal. Chem. 2014, 86, 2657-64
58. Sanderson, R. J.; Hering, M. A.; James, S. F.; Sun, M. M.; Doronina, S. O.; Siadak, A. W.; Senter, P. D.; Wahl, A. F. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate Clin. Cancer Res. 2005, 11, 843-52
59. Hernandez, H.; Dziembowski, A.; Taverner, T.; Seraphin, B.; Robinson, C. V. Subunit architecture of multimeric complexes isolated directly from cells EMBO Rep. 2006, 7, 605-10
60. van Duijn, E.; Bakkes, P. J.; Heeren, R. M.; van den Heuvel, R. H.; van Heerikhuizen, H.; van der Vies, S. M.; Heck, A. J. Monitoring macromolecular complexes involved in the chaperonin-assisted protein folding cycle by mass spectrometry Nat. Methods 2005, 2, 371-6
61. Zhang, H.; Cui, W.; Wen, J.; Blankenship, R. E.; Gross, M. L. Native electrospray and electron-capture dissociation FTICR mass spectrometry for top-down studies of protein assemblies Anal. Chem. 2011, 83, 5598-606
62. Boys, B. L.; Konermann, L. Folding and assembly of hemoglobin monitored by electrospray mass spectrometry using an on-line dialysis system J. Am. Soc. Mass Spectrom. 2007, 18, 8-16
63. Munoz, I. G.; Yebenes, H.; Zhou, M.; Mesa, P.; Serna, M.; Park, A. Y.; Bragado-Nilsson, E.; Beloso, A.; de Carcer, G.; Malumbres, M. Crystal structure of the open conformation of the mammalian chaperonin CCT in complex with tubulin Nat. Struct. Mol. Biol. 2011, 18, 14-9
64. Brady, L. J.; Valliere-Douglass, J.; Martinez, T.; Balland, A. Molecular mass analysis of antibodies by on-line SEC-MS J. Am. Soc. Mass Spectrom. 2008, 19, 502-9
65. Alley, S. C.; Anderson, K. E. Analytical and bioanalytical technologies for characterizing antibody-drug conjugates Curr. Opin. Chem. Biol. 2013, 17, 406-11
66. Gorovits, B.; Alley, S. C.; Bilic, S.; Booth, B.; Kaur, S.; Oldfield, P.; Purushothama, S.; Rao, C.; Shord, S.; Siguenza, P. Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper Bioanalysis 2013, 5, 997-1006
67. Zhao, R. Y.; Wilhelm, S. D.; Audette, C.; Jones, G.; Leece, B. A.; Lazar, A. C.; Goldmacher, V. S.; Singh, R.; Kovtun, Y.; Widdison, W. C. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates J. Med. Chem. 2011, 54, 3606-23
68. Alley, S. C.; Benjamin, D. R.; Jeffrey, S. C.; Okeley, N. M.; Meyer, D. L.; Sanderson, R. J.; Senter, P. D. Contribution of linker stability to the activities of anticancer immunoconjugates Bioconjugate Chem. 2008, 19, 759-65
69. Xu, K.; Liu, L.; Dere, R.; Mai, E.; Erickson, R.; Hendricks, A.; Lin, K.; Junutula, J. R.; Kaur, S. Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum Bioanalysis 2013, 5, 1057-71
70. Joubert, M. K.; Luo, Q.; Nashed-Samuel, Y.; Wypych, J.; Narhi, L. O. Classification and characterization of therapeutic antibody aggregates J. Biol. Chem. 2011, 286, 25118-33
71. van Beers, M. M.; Bardor, M. Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins Biotechnol. J. 2012, 7, 1473-84
72. Bhabha, G.; Lee, J.; Ekiert, D. C.; Gam, J.; Wilson, I. A.; Dyson, H. J.; Benkovic, S. J.; Wright, P. E. A dynamic knockout reveals that conformational fluctuations influence the chemical step of enzyme catalysis Science 2011, 332, 234-8
73. Henzler-Wildman, K.; Kern, D. Dynamic personalities of proteins Nature 2007, 450, 964-72
74. Ionescu, R. M.; Vlasak, J.; Price, C.; Kirchmeier, M. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies J. Pharm. Sci. 2008, 97, 1414-26
75. Wakankar, A. A.; Feeney, M. B.; Rivera, J.; Chen, Y.; Kim, M.; Sharma, V. K.; Wang, Y. J. Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes Bioconjugate Chem. 2010, 21, 1588-95
76. Zhang, Z.; Smith, D. L. Determination of amide hydrogen exchange by mass spectrometry: a new tool for protein structure elucidation Protein Sci. 1993, 2, 522-31
77. Kaltashov, I. A.; Bobst, C. E.; Abzalimov, R. R.; Berkowitz, S. A.; Houde, D. Conformation and dynamics of biopharmaceuticals: transition of mass spectrometry-based tools from academe to industry J. Am. Soc. Mass Spectrom. 2010, 21, 323-37
78. Zhang, A.; Qi, W.; Singh, S. K.; Fernandez, E. J. A new approach to explore the impact of freeze-thaw cycling on protein structure: hydrogen/deuterium exchange mass spectrometry (HX-MS) Pharm. Res. 2011, 28, 1179-93
79. Guo, J.; Kumar, S.; Prashad, A.; Starkey, J.; Singh, S. K. Assessment of Physical Stability of an Antibody Drug Conjugate by Higher Order Structure Analysis: Impact of Thiol- Maleimide Chemistry Pharm. Res. 2014, 31 (7) 1710-23
80. Beckley, N. S.; Lazzareschi, K. P.; Chih, H. W.; Sharma, V. K.; Flores, H. L. Investigation into temperature-induced aggregation of an antibody drug conjugate Bioconjugate Chem. 2013, 24, 1674-83
81. Goetze, A. M.; Liu, Y. D.; Arroll, T.; Chu, L.; Flynn, G. C. Rates and impact of human antibody glycation in vivo Glycobiology 2012, 22, 221-34
82. Goetze, A. M.; Liu, Y. D.; Zhang, Z.; Shah, B.; Lee, E.; Bondarenko, P. V.; Flynn, G. C. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans Glycobiology 2011, 21, 949-59